Manufacturer of intravascular products selects clinivation Global xi to manage its medical products approvals and submissions.
Natick, MA, August 7, 2007 – clinivation, Inc. announced today that Volcano Corporation (NASDAQ: VOLC) has selected the clinivation Global Enterprise Solution for Market Clearance Management Market Clearance Management solution.”Volcano has developed next-generation products that enhance the diagnosis and treatment of vascular and structural heart disease,” said Joseph Kozikowski, M.D., clinivation’s
Chief Executive Officer. “We are delighted Volcano’s senior management has selected clinivation Global xi to help impact market clearance operations to better achieve sales and marketing objectives,” he continued.
Clinivation Global xi software enables medical device companies to sell more products to more countries faster and easier than ever before. Clinivation Global xi is the first complete solution targeted at automating the business processes for market clearance operations worldwide.
About Volcano Corporation
Volcano Corporation offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart diseases and guide optimal therapies. The company’s intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab. Volcano IVUS offers unique features, including both single-use phased array and rotational IVUS imaging catheters, and advanced functionality options, such as VH(TM) IVUS tissue characterization. Volcano also provides functional measurement (FM) consoles and single-use pressure and flow guide wires. Currently, more than 2,700 Volcano IVUS and FM systems are installed worldwide, with approximately half of its revenues coming from outside the United States.
For more information, visit the company’s website at www.volcanocorp.com.